source
- Big tech and startups are building personal AI agents to analyze patients’ medical recordsIn a recent column the author notes that personal artificial-intelligence agents are poised to enter the healthcare arena. Large technology firms and emerging startups are creating platforms that…
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…